Next earnings date: 22 Oct 2025

Xvivo Perfusion AB (publ) – LSE:0RKL.L

Add to watchlist

SEK 275

-205.73

-42.8%

Market open

Closed in 44 minutes

-5.10%

month

-5.10%

quarter

+51.65%

year

Market Cap	14.89B
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	3.82

Revenue	698.72M
EBITDA	79.69M
Income	120.73M
Revenue Q/Q	36.08%
Revenue Y/Y	33.46%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	11.41%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Xvivo Perfusion AB (publ) (LSE:0RKL.L): Profit margin
Sep 2023	146.61M	2.28M	1.56%
Dec 2023	155.74M	68.47M	43.97%
Mar 2024	186.02M	22.78M	12.25%
Jun 2024	210.34M	27.19M	12.93%

Xvivo Perfusion AB (publ) Financials Estimate

Q Y

Xvivo Perfusion AB (publ) (LSE:0RKL.L): Analyst Estimates
2025	1.08B	166.83M	15.38%
2026	1.47B	268.03M	18.15%
2027	2.17B	0
2028	2.48B	0

Analysts Price target
Financials & Ratios estimates

Xvivo Perfusion AB (publ) (LSE:0RKL.L): Debt to assets
Sep 2023	2237108000	308.99M	13.81%
Dec 2023	2195611000	250.56M	11.41%
Mar 2024	2253686000	250.54M	11.12%
Jun 2024	2272986000	248.18M	10.92%

Xvivo Perfusion AB (publ) (LSE:0RKL.L): Cash Flow
Sep 2023	24.84M	-28.08M	427.62M
Dec 2023	18.12M	-52.58M	-3.72M
Mar 2024	1.59M	-42.49M	-2.36M
Jun 2024	24.73M	-48.43M	-3.52M

Xvivo Perfusion AB (publ) alternative data

Xvivo Perfusion AB (publ)
Employees

Xvivo Perfusion AB (publ) (LSE:0RKL.L): Employee count
Aug 2023	142
Sep 2023	142
Oct 2023	142
Nov 2023	144
Dec 2023	144
Jan 2024	144
Feb 2024	150
Mar 2024	150
Apr 2024	150
May 2024	148
Jun 2024	148
Jul 2024	148

Xvivo Perfusion AB (publ)
Executives

Insider	Age	Since	Compensation
Dr. Magnus Nilsson Senior Advisor
Mr. Dag Andersson Pres & Chief Executive Officer
Mr. Christoffer Rosenblad Chief Financial Officer & Board Sec.
Mr. Andreas Wallinder M.D., Ph.D. Chief Medical Officer
Mr. Johan Holmstrom C.C.O
Mr. Christer de Flon Mang.
Ms. Katrin Gisselfalt Quality & Regulatory Director

Frequently Asked Questions (FAQ)

What's the price of Xvivo Perfusion AB (publ) stock today?

One share of Xvivo Perfusion AB (publ) stock can currently be purchased for approximately $275.
When is Xvivo Perfusion AB (publ)'s next earnings date?

Xvivo Perfusion AB (publ) is estimated to report earnings on Wednesday, 22 Oct 2025.
Does Xvivo Perfusion AB (publ) pay dividends?

No, Xvivo Perfusion AB (publ) does not pay dividends.
How much money does Xvivo Perfusion AB (publ) make?

Xvivo Perfusion AB (publ) has a market capitalization of 14.89B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 43.88% to 597.54M US dollars.
What is Xvivo Perfusion AB (publ)'s stock symbol?

Xvivo Perfusion AB (publ) is traded on the LSE under the ticker symbol "0RKL.L".
What is Xvivo Perfusion AB (publ)'s primary industry?

Company operates in the Healthcare sector and Medical - Equipment & Services industry.
How do i buy shares of Xvivo Perfusion AB (publ)?

Shares of Xvivo Perfusion AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Xvivo Perfusion AB (publ)'s key executives?
Xvivo Perfusion AB (publ)'s management team includes the following people:
- Dr. Magnus Nilsson Senior Advisor
- Mr. Dag Andersson Pres & Chief Executive Officer
- Mr. Christoffer Rosenblad Chief Financial Officer & Board Sec.
- Mr. Andreas Wallinder M.D., Ph.D. Chief Medical Officer
- Mr. Johan Holmstrom C.C.O
- Mr. Christer de Flon Mang.
- Ms. Katrin Gisselfalt Quality & Regulatory Director
How many employees does Xvivo Perfusion AB (publ) have?

As Jul 2024, Xvivo Perfusion AB (publ) employs 148 workers, which is 1% less then previous quarter.
When Xvivo Perfusion AB (publ) went public?

Xvivo Perfusion AB (publ) is publicly traded company for more then 8 years since IPO on 8 Dec 2016.
What is Xvivo Perfusion AB (publ)'s official website?

The official website for Xvivo Perfusion AB (publ) is xvivoperfusion.com.
How can i contact Xvivo Perfusion AB (publ)?

Xvivo Perfusion AB (publ) can be reached via phone at +46 31 788 21 50.

Xvivo Perfusion AB (publ)

xvivoperfusion.com

Exchange:

LSE

Full time employees:

161

Industry:

Medical - Equipment & Services

Sector:

Healthcare

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

+46 31 788 21 50

MAessans gata 10
Gothenburg, 412 51

:
ISIN: SE0004840718
CUSIP: W989AP102